Elevance Health (Elevance) is one of the largest health insurers in the US, serving approximately 46m members. The healthcare industry is currently going through a tough period as utilisation has increased with lagging price adjustments, therefore leading to what we deem to be cyclically low margins for Elevance, due to elevated medical loss ratios. This has been further compounded by significant regulatory noise which, based on our analysis, won’t have a material impact on Elevance. Both of these factors have created what we deem short-term cyclical headwinds allowing us to purchase the business on 9x forward earnings, which should grow at a high teens rate as margins normalise.


Insights Disclaimer



Related articles

The case for Dis-Chem

Last year in May, Marie covered South Africa’s water crisis, with a deep dive into the pain points and responsible agencies. This concern has not abated and has grave consequences for SA and its citizens. Our 2023 Stewardship report covers our ongoing analysis of SA’s water crisis and how our investment team is addressing it in the context of investments.